CDKN2A and acute lymphoblastic leukemia: Due to the high prevalence of CDKN2A/B deletions in ALL patients and the fact that they are involved in regulating the cell cycle, we might have envisaged a potential use of INK4 family members as targets for exploring specific related therapies to treat ALL.